HIGHLIGHTS
- who: Chien-Yu Lin from the Hospital of the Chinese People's Liberation Army, China Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine have published the research work: Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin, in the Journal: (JOURNAL)
- future: Prospective clinical trials are warranted to validate these results. response to crizotinib among NSCLC patients with de noo MET fusion .
SUMMARY
Telisotuzumab vedotin, previously named ABBV-399, is an antibody-drug conjugate, which comprises a human METtargeting . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.